Predicted to enable neuropeptide binding activity; pancreatic polypeptide receptor activity; and peptide YY receptor activity. Involved in several processes, including positive regulation of cholesterol biosynthetic process; regulation of presynaptic cytosolic calcium ion concentration; and regulation of secretion by cell. Located in axon and synaptic vesicle. Is active in glutamatergic synapse; neuronal dense core vesicle; and presynaptic membrane. Used to study absence epilepsy; anxiety disorder; depressive disorder; and hypertension. Biomarker of obesity. Human ortholog(s) of this gene implicated in amphetamine abuse; cocaine abuse; heroin dependence; nicotine dependence; and opiate dependence. Orthologous to human NPY1R (neuropeptide Y receptor Y1); INTERACTS WITH 17beta-estradiol; 1D-myo-inositol 1,4,5-trisphosphate; 2,3,7,8-tetrachlorodibenzodioxine.
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb more ...
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of more ...
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of more ...
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of more ...
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NPY1R mRNA; [Coumestrol co-treated with ESR1 more ...
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb more ...
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression more ...
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with monobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-isobutyl more ...
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with monobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-isobutyl more ...
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with monobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-isobutyl more ...
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with monobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-isobutyl more ...
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression more ...
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased more ...
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb more ...
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression more ...
[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of more ...
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb more ...
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased more ...
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb more ...
The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression.
Expression of neuropeptide Y and its receptors Y1 and Y2 in the rat heart and its supplying autonomic and spinal sensory ganglia in experimentally induced diabetes.
Ultrastructural localization of neuropeptide Y Y1 receptors in the rat medial nucleus tractus solitarius: relationships with neuropeptide Y or catecholamine neurons.
Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression.
Differential regulation of mRNAs for neuropeptide Y and its receptor subtypes in widespread areas of the rat limbic system during kindling epileptogenesis.
Gene Expression Changes in Glutamate and GABA-A Receptors, Neuropeptides, Ion Channels, and Cholesterol Synthesis in the Periaqueductal Gray Following Binge-Like Alcohol Drinking by Adolescent Alcohol-Preferring (P) Rats.
Polymorphisms in Stress-Related Genes Are Associated with Reduced Cocaine Abuse and Longer Retention in Methadone Maintenance Treatment for Opioid Use Disorder.
Modulation of intracellular calcium changes and glutamate release by neuropeptide Y1 and Y2 receptors in the rat hippocampus: differential effects in CA1, CA3 and dentate gyrus.
Acute stress and alcohol exposure during adolescence result in an anxious phenotype in adulthood: Role of altered glutamate/endocannabinoid transmission mechanisms.
Ultrastructural Characterization of Corticotropin-Releasing Factor and Neuropeptide Y in the Rat Locus Coeruleus: Anatomical Evidence for Putative Interactions.
Activation of neuropeptide Y Y1 receptors inhibits glutamate release through reduction of voltage-dependent Ca2+ entry in the rat cerebral cortex nerve terminals: suppression of this inhibitory effect by the protein kinase C-dependent facilitatory pathway.